These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 4739850

  • 1. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
    Földes J, Gyertyánfy G, Tako J, Bános C, Gesztesi E.
    Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
    [No Abstract] [Full Text] [Related]

  • 2. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC, Kannan V, Rastogi GK.
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract] [Full Text] [Related]

  • 3. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I.
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [Abstract] [Full Text] [Related]

  • 4. Serum ferritin, iron and transferrin in women with thyrotoxic Graves' disease before and after methimazole treatment.
    Zwirska-Korczala K, Buntner B, Sobieraj H, Ostrowska Z, Kniazewski B, Swietochowska E.
    Acta Physiol Pol; 1990 Apr; 41(7):163-8. PubMed ID: 2136311
    [Abstract] [Full Text] [Related]

  • 5. Thyroid gland in Graves' disease: victim or culprit?
    Chopra IJ, Solomon DH, Johnson DE, Chopra U.
    Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
    [No Abstract] [Full Text] [Related]

  • 6. T4-thyrotoxicosis.
    Dorfman SG, Young RL.
    Arch Intern Med; 1978 Jun; 138(6):1016-7. PubMed ID: 580554
    [Abstract] [Full Text] [Related]

  • 7. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, Mozai T, Hershman JM.
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [Abstract] [Full Text] [Related]

  • 8. [Proceedings: Blood T3-T4 ratio in various states of thyroid function].
    Tanaka K, Mashimo K, Kishino F, Nishiooeda Y, Tarui S.
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb 20; 50(2):116. PubMed ID: 4480291
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun 20; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 10. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW.
    Clin Endocrinol (Oxf); 2005 May 20; 62(5):521-4. PubMed ID: 15853819
    [Abstract] [Full Text] [Related]

  • 11. Triiodothyronine antibodies in a case of Graves' disease: long-term follow-up under carbimazole.
    Heshmati HM, Izembart M, Turpin G, Vallée G.
    Horm Metab Res; 1991 Mar 20; 23(3):148. PubMed ID: 1864563
    [No Abstract] [Full Text] [Related]

  • 12. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
    Chopra IJ, Chopra U, Orgiazzi J.
    J Clin Endocrinol Metab; 1973 Dec 20; 37(6):955-67. PubMed ID: 4201831
    [No Abstract] [Full Text] [Related]

  • 13. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
    Wong ET, Doe RP.
    Ann Intern Med; 1972 Jan 20; 76(1):77-84. PubMed ID: 4112158
    [No Abstract] [Full Text] [Related]

  • 14. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease.
    Sewerynek J, Wiktorska J, Nowak D, Lewinski A.
    Endocr Regul; 2000 Jun 20; 34(2):83-9. PubMed ID: 10911409
    [Abstract] [Full Text] [Related]

  • 15. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb 20; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 16. Graves' disease associated with elevated serum thyroxine-binding globulin concentrations.
    Yabu Y, Amino N, Nakatani K, Ichihara K, Azukizawa M, Miyai K.
    J Clin Endocrinol Metab; 1980 Aug 20; 51(2):325-9. PubMed ID: 6772663
    [No Abstract] [Full Text] [Related]

  • 17. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N, Chiu SC, Ikeda H, Uchimura H, Ito K, Nagataki S.
    J Clin Endocrinol Metab; 1979 Apr 20; 48(4):706-11. PubMed ID: 581876
    [No Abstract] [Full Text] [Related]

  • 18. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct 20; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 19. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G, Jie Y, Situ Y.
    Zhonghua Yi Xue Za Zhi; 2001 Mar 10; 81(5):274-5. PubMed ID: 11798886
    [Abstract] [Full Text] [Related]

  • 20. Laboratory examination of the thyroid. 1. In vitro tests.
    Schneider PB.
    Postgrad Med; 1974 Aug 10; 56(2):91-6. PubMed ID: 4136847
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.